Disease · MONDO_0005010
Comparisons in its trials79
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 79
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Rosuvastatin 40 mg vs Atorvastatin 80 mg: Numbers of Patients Showing Regression in TAV | 371 of 520 | 336 of 519 | 1,039 | NCT00620542 | Trial comparisons |
| Rosuvastatin 40 mg vs Atorvastatin 80 mg: Numbers of Patients Showing Regression in PAV | 356 of 520 | 328 of 519 | 1,039 | NCT00620542 | Trial comparisons |
| Standard Therapy vs Individualized Therapy: Any Bleeding Event | 17 of 664 | 9 of 343 | 1,007 | NCT01515345 | Trial comparisons |
| Standard Therapy vs Individualized Therapy: Probable Stent Thrombosis | 2 of 664 | 0 of 343 | 1,007 | NCT01515345 | Trial comparisons |
| Standard Therapy vs Individualized Therapy: Definite Stent Thrombosis | 1 of 664 | 0 of 343 | 1,007 | NCT01515345 | Trial comparisons |
| Standard Therapy vs Individualized Therapy: serious adverse events | 26 of 664 | 18 of 343 | 1,007 | NCT01515345 | Trial comparisons |
| Evolocumab vs Placebo: serious adverse events | 135 of 484 | 142 of 484 | 968 | NCT01813422 | Trial comparisons |
| Dalcetrapib vs Placebo: serious adverse events | 61 of 474 | 63 of 462 | 936 | NCT01059682 | Trial comparisons |
| Aliskiren 300 mg vs Placebo: serious adverse events | 76 of 305 | 97 of 308 | 613 | NCT00853827 | Trial comparisons |
| Dalcetrapib vs Placebo: deaths from any cause | 0 of 236 | 1 of 236 | 472 | NCT00655538 | Trial comparisons |
| Dalcetrapib vs Placebo: serious adverse events | 12 of 236 | 14 of 236 | 472 | NCT00655538 | Trial comparisons |
| Aliskiren vs Placebo: Patients That Demonstrated Evidence of Atheroma Regression | 128 of 225 | 114 of 233 | 458 | NCT00853827 | Trial comparisons |
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin 10 or 20 mg: Number of Participants Who Reached the LDL-C Level of <70 mg/dl | 96 of 219 | 38 of 217 | 436 | NCT00783263 | Trial comparisons |
| Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin (10 or 20 mg): Number of Participants Who Reached Their Target LDL-C Level | 130 of 219 | 67 of 217 | 436 | NCT00783263 | Trial comparisons |
| Prasugrel vs Clopidogrel: Number of Participants With Composite Endpoint of Cardiovascular Death or Myocardial Infarction (MI) | 0 of 212 | 1 of 211 | 423 | NCT00910299 | Trial comparisons |
| Prasugrel vs Clopidogrel: Number of Participants With Stent Thrombosis (ST) | 0 of 212 | 0 of 211 | 423 | NCT00910299 | Trial comparisons |
| Prasugrel vs Clopidogrel: Number of Participants With Composite Endpoint of All-Cause Death or Myocardial Infarction (MI) | 0 of 212 | 2 of 211 | 423 | NCT00910299 | Trial comparisons |
| Prasugrel vs Clopidogrel: serious adverse events | 40 of 210 | 38 of 210 | 420 | NCT00910299 | Trial comparisons |
| Darapladib 160 mg EC Tablet vs Placebo: deaths from any cause | 0 of 172 | 0 of 151 | 323 | NCT00268996 | Trial comparisons |
| Darapladib 160 mg EC Tablet vs Placebo: serious adverse events | 46 of 172 | 45 of 151 | 323 | NCT00268996 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005010/comparisons